Skip to main content
Announcements

Sidley Represents Starna Therapeutics in Licensing Agreement With Pfizer Valued at Up to US$2.6 Billion

November 19, 2026

Sidley represented Starna Therapeutics Co., Ltd., a China-based biotechnology company developing innovative therapeutics using proprietary RNA delivery technologies, in an exclusive licensing agreement with Pfizer Inc. valued at up to approximately US$2.6 billion, plus royalties. The agreement includes a US$330 million upfront payment and up to US$2.3 billion in potential milestone payments. Under the agreement, Pfizer will receive exclusive rights to develop, manufacture, and commercialize three of Starna’s investigational in vivo chimeric antigen receptor T-cell (CAR-T) programs outside Greater China. The collaboration also provides Pfizer with rights to use Starna’s proprietary technology in inflammation, immunology, and oncology, supporting the development of potential new therapies for autoimmune diseases and cancer.

The Sidley team was led by Lila Hope and Jennifer Raab (Technology and Life Sciences Transactions), and included Yuhan Wu (Technology and Life Sciences Transactions).


関連リソース